-transparent.png){kind=logo}
Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) was administered in a dose of 20 mg/kg/d to 21 patients with symptomatic Paget's disease. All patients were treated for 6 months and then followed for an additional 6 months. There was a striking decline in serum alkaline phosphatase and urinary hydroxy-proline excretion observed after 3 months of therapy which was not significantly improved in the succeeding 3 months. Concomitantly there was marked improvement in clinical symptoms and bone scans. Following cessation of therapy, continued biochemical and clinical evidence of remission persisted. Several patients on repeat treatment with EHDP appeared to respond promptly. Side effects were minimal except for a possibly related osteomalacia and increased incidence of pathologic fractures.
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
January 1976,
Minerva medica,
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
January 1972,
Seminars in drug treatment,
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
August 1987,
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
December 1982,
The Journal of clinical endocrinology and metabolism,
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
September 1988,
BMJ (Clinical research ed.),
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
February 1979,
Australian and New Zealand journal of medicine,
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
January 1977,
The Journal of clinical endocrinology and metabolism,
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
January 1981,
Metabolic bone disease & related research,
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
October 1985,
Revista clinica espanola,
G A Finerman, and
H C Gonick, and
R K Smith, and
J M Mayfield
February 1982,
Revue du rhumatisme et des maladies osteo-articulaires,
